Left Ventricular Hypertrophy Clinical Trial
Official title:
Protective Gr1low Monocytes and Macrophages in Compensated Cardiac Hypertrophy to Limit Decompensation and Heart Damaging
The working hypothesis is that cardiac macrophages specific for the compensated cardiac hypertrophic phase limit the progression toward the decompensated state of heart failure by promoting an inflammatory environment favouring cardiomyocyte survival and preservation of the pump function. The investigators will perform studies in human plasma and monos, cardiac tissues and macrophages to validate this hypothesis.
Left ventricular hypertrophy (LVH) occurs following acute and chronic phases of ischemic
heart disease as well as during pressure and/or volume overload (arterial hypertension,
valvular heart disease). Persistence of the pathological stimuli, i.e. pressure and/or volume
overload, will ultimately lead to the decompensation of cardiac function described as heart
failure (HF). HF is worldwide one of the major healthcare concerns both in terms of the loss
of human life and economic burden due to the expanding costs of care for patients with this
condition (Ambrosy 2014). HF is associated with cardiomyocyte death, exacerbated inflammatory
reaction with ensuing fibrosis and alteration of local angiogenesis. A better understanding
of the mechanisms involved in the maintenance of the compensated state and in the transition
to heart failure will promote the conception of new pharmacological interventions to prevent
or even to reverse the transition to heart failure. Based on preclinical studies, the aim of
this study is to advance our knowledge of relevant mechanisms involved in this process.
In an experimental setting in mice, the protective role of macrophages presenting an
anti-inflammatory polarization in the progression of isuprel-induced left ventricular
hypertrophy to irreversible heart failure has been recently demonstrated (Keck et al.,
submitted). These findings in the experimental model encourage their confirmation in the
clinical setting. In the latter case, new therapeutic strategies can be projected to prevent
or even to reverse the transition of compensated cardiac hypertrophy to heart failure.
To this purpose, the investigators will study cardiac tissue and blood sample of patients
presenting compensated cardiac hypertrophy compared to those with end-stage heart failure.
Patients undergoing aortic valve replacement associated with septal myomectomy for aortic
valve stenosis and asymmetric septal hypertrophy as well as patients with hypertrophic
obstructive cardiomyopathy (HOCM) undergoing septal myomectomy are included in the group of
compensated cardiac hypertrophy. Patients undergoing heart transplantation or implantation of
mechanical life supporting system are included in the group of end-stage heart failure.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03549559 -
Imaging Histone Deacetylase in the Heart
|
N/A | |
Completed |
NCT03332745 -
Mechanism of Decompensation Evaluation - Aortic Stenosis
|
||
Completed |
NCT03322319 -
Frequency of Cardiac Amyloidosis in the Caribbean's. (TEAM Amylose)
|
N/A | |
Completed |
NCT01951404 -
Does ALlopurinol Regress lefT Ventricular Hypertrophy in End Stage REnal Disease: The ALTERED Study
|
Phase 4 | |
Terminated |
NCT01188369 -
Effects of Levosimendan in Patients Eligible for Aortic Valve Replacement With Left Ventricular Hypertrophy
|
Phase 4 | |
Completed |
NCT00344903 -
Dallas Heart Study 2: Return Clinic Visit for the Dallas Heart Study Cohort
|
N/A | |
Completed |
NCT00518479 -
Pathophysiological Mechanisms of Hypertensive LVH:Optimising Regression
|
N/A | |
Completed |
NCT00001632 -
Investigation Into the Use of Ultrasound Technique in the Evaluation of Heart Disease
|
N/A | |
Completed |
NCT00001534 -
Long Term Effects of Enalapril and Losartan on Genetic Heart Disease
|
N/A | |
Suspended |
NCT03193073 -
Anemia Correction and Fibroblast Growth Factor 23 Levels in Chronic Kidney Disease , and Renal Transplant Patient
|
N/A | |
Enrolling by invitation |
NCT05903313 -
A Study to Evaluate Accuracy and Validity of the Chang Gung ECG Abnormality Detection Software
|
||
Recruiting |
NCT05646056 -
A Noninterventional, Single-Center Feasibility Study to Evaluate Measures of Heart Failure Risk
|
||
Completed |
NCT01455974 -
The Effects of Lowering Dialysate Sodium in Hypertensive Hemodialysis Patients
|
N/A | |
Active, not recruiting |
NCT00418041 -
Chronic Heart Failure Analysis and Registry in the Tohoku District 2 (CHART-2 Study)
|
N/A | |
Completed |
NCT00602004 -
Attenuation of Cardiac Effects of Arteriovenous Fistula Creation With Losartan
|
N/A | |
Completed |
NCT00219141 -
Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension
|
Phase 3 | |
Completed |
NCT03666351 -
Study to Evaluate the Effect on Improvement of LVH by the Control of BP in Hypertension Patients With AV Disease
|
Phase 4 | |
Recruiting |
NCT05730309 -
Point-of-care Ultrasound and Treatment Disparities for Left Ventricular Hypertrophy
|
N/A | |
Recruiting |
NCT06169358 -
Screening Patients With Fabry Disease in Patients With Hypertrophic Cardiomyopathy or Left Ventricular Hypertrophy
|
||
Recruiting |
NCT05179668 -
SGLT2 Inhibition in Hemodialysis
|
Phase 2 |